Tenaya Therapeutics — Third Quarter 2026 Earnings Summary

Tenaya Therapeutics reported a net loss of $18.9 million for the third quarter of 2026, with cash and cash equivalents totaling $66.8 million as of September 30, 2026. The company received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. FDA for its TN-401 gene therapy candidate targeting PKP2-associated arrhythmogenic right ventricular cardiomyopathy. Management plans to report longer-term clinical data for TN-201 and TN-401 by year-end and expects to initiate Phase 2 trials for TN-301 in the second half of 2027. These financial resources are projected to fund the company's operations through the fourth quarter of 2027.